10 Common 340B Billing Mistakes Hospitals Should Avoid

Last Updated on November 12, 2026

A hospital may have accurate drug purchasing records and still face 340B billing problems. A claim submitted under the wrong Medicaid billing identifier, an unsupported eligible encounter, or an unreconciled drug transaction can create financial exposure that routine payment reports may not detect.

The most important 340B billing mistakes hospitals should avoid involve incorrect patient eligibility, unregistered service locations, Medicaid duplicate discounts, drug coding and unit errors, inaccurate modifiers, weak inventory reconciliation, and insufficient contract pharmacy oversight.

These mistakes affect different parts of hospital operations. Some threaten eligibility for 340B discounts, while others cause reimbursement discrepancies or audit findings. Recognizing the difference helps hospital finance, pharmacy, and revenue cycle leaders apply the right corrective controls.

Why 340B Billing Mistakes Create More Than Claim Denials

The 340B Drug Pricing Program allows eligible covered entities to purchase qualifying outpatient drugs at discounted prices. Participation requires compliance with applicable program requirements, including restrictions on diversion and duplicate discounts.

For hospitals, the consequences of billing errors extend beyond rejected claims. Common 340B billing challenges can affect purchasing accuracy, Medicaid reporting, and reconciliation across pharmacy and revenue cycle systems.

A hospital must distinguish three types of financial exposure:

HRSA requires covered entities to maintain accurate registration information, prevent diversion and duplicate discounts, and retain auditable records. 

For hospitals managing outpatient pharmacy operations, 340B program billing requires coordination between eligibility determination, pharmacy systems, claims processing, and financial reconciliation.

Ten 340B Billing Mistakes and the Controls Hospitals Need

The following mistakes are organized around where they create risk, rather than treating every issue as a claim processing problem.

Mistake 1. Incorrect Patient Eligibility Determination

A patient receiving a drug at a hospital does not automatically qualify for 340B purchasing.

Eligibility depends on the covered entity’s relationship with the patient, responsibility for care, and applicable program requirements. Incorrect encounter classification or unsupported prescribing relationships can result in diversion.

Financial exposure: Ineligible 340B purchases may require repayment to manufacturers.

Preventive control: Validate patient eligibility against clinical encounter records, provider relationships, and documented eligibility criteria before assigning 340B transactions.

Hospitals can strengthen this process through encounter eligibility determination, supported by documented exception review.

Mistake 2. Using 340B Drugs for Ineligible Locations

Hospitals may administer or dispense drugs across multiple outpatient departments, clinics, and provider-based locations.

A location’s association with a hospital does not automatically establish its eligibility for 340B purchasing. Applicable registration and eligibility requirements must be satisfied.

Financial exposure: Drug purchases associated with ineligible sites can create diversion findings and repayment exposure.

Preventive control: Reconcile active service locations against HRSA registration records and applicable eligibility documentation. Review changes when clinics open, close, relocate, or change operational status.

Mistake 3. Incorrect Medicaid Carve-In and Carve-Out Reporting

Hospitals must distinguish Medicaid fee-for-service claims involving 340B drugs from claims involving drugs purchased through other arrangements.

A mismatch between actual billing practices and the information reported to HRSA can create duplicate discount risk.

Financial exposure: Incorrect Medicaid billing identification may result in compliance findings and manufacturer repayment obligations.

Preventive control: Validate each applicable covered entity site’s Medicaid carve-in or carve-out election, billing identifiers, and effective quarter against HRSA’s Medicaid Exclusion File.

The Medicaid Exclusion File applies to Medicaid fee-for-service, not Medicaid managed care. Managed care duplicate discount prevention requires separate controls.

Mistake 4. Failing to Prevent Duplicate Discounts

A prohibited duplicate discount occurs when a manufacturer provides a 340B discount and a Medicaid drug rebate for the same drug.

This can arise when billing identifiers, claim indicators, or Medicaid arrangements do not properly identify 340B utilization.

Financial exposure: Duplicate discounts can lead to audit findings and repayment requirements.

Preventive control: Establish transaction-level duplicate discount prevention across applicable Medicaid fee-for-service and managed care arrangements.

Reconcile 340B drug transactions with claim-level information and applicable state requirements rather than relying solely on the Medicaid Exclusion File.

Mistake 5. Incorrect Drug Codes and Billing Units

Hospital outpatient drug claims may require accurate HCPCS codes, National Drug Codes, billing units, and applicable modifiers.

Errors occur when administered quantities are converted incorrectly into HCPCS units or when drug information does not match the clinical and charge records.

Financial exposure: Incorrect units or drug identification can cause underbilling, overbilling, denials, or payment adjustments.

Preventive control: Reconcile documented drug administration, NDC information where required, HCPCS units, and charge records before claim submission.

Accurate drug charge capture and coding requires consistent unit conversions and validation against payer-specific reporting requirements.

Mistake 6. Applying Incorrect 340B Claim Modifiers

340B-related modifier requirements vary by payer, service date, provider type, and applicable payment policy.

Using outdated modifier instructions can create claim reporting discrepancies, even when the underlying drug transaction is eligible.

Financial exposure: Incorrect claim identification may result in rejected claims, reporting errors, or payment adjustments.

Preventive control: Maintain a payer-specific modifier reference that identifies applicable requirements and effective dates.

For example, CMS discontinued Medicare OPPS modifier JG reporting effective January 1, 2025, while modifier TB reporting continues under applicable requirements. State Medicaid rules may differ. 

Hospitals should validate current instructions before applying any modifier across all drug claims.

Mistake 7. Poor Mixed-Use Inventory Reconciliation

Hospitals may use the same drug across eligible outpatient encounters, ineligible encounters, and different purchasing accounts.

When drug utilization, accumulation, and replenishment records do not reconcile, inventory discrepancies can affect 340B purchasing accuracy.

Financial exposure: Incorrect accumulations can create unsupported purchasing, inventory imbalances, or missed eligible savings.

Preventive control: Reconcile eligible utilization against purchasing and replenishment records, including NDC-level quantities and documented exceptions.

Consistent mixed-use account reconciliation helps identify discrepancies before they accumulate across reporting periods.

Mistake 8. Inadequate Contract Pharmacy Oversight

Contract pharmacy arrangements introduce additional transaction and data reconciliation requirements.

A hospital remains responsible for ensuring its contract pharmacy arrangements comply with applicable 340B requirements, including preventing diversion and duplicate discounts.

Financial exposure: Unsupported dispensing or inaccurate eligibility determinations can create audit findings and repayment exposure.

Preventive control: Effective contract pharmacy and TPA management requires reconciling dispensing records, eligibility determinations, purchasing activity, and transaction exceptions.

HRSA recommends quarterly internal audits and annual independent audits of utilized contract pharmacies, or more frequent reviews when necessary. 

Mistake 9. Overlooking Drug Reimbursement Discrepancies

A correctly purchased 340B drug can still be billed incorrectly or reimbursed below the amount supported by the applicable payment methodology.

Hospitals should not assume that discounted acquisition cost determines payer reimbursement. These are separate financial calculations.

Financial exposure: Incorrect allowed amounts, units, or contractual adjustments may produce payment variances.

Preventive control: Compare actual adjudication with applicable Medicare or commercial payer payment terms.

Focused hospital underpayment recovery can help investigate validated payment discrepancies without treating every variance as recoverable revenue.

Mistake 10. Maintaining Incomplete Audit and Exception Records

Even when purchasing and billing decisions are correct, hospitals need records that support those decisions.

Incomplete eligibility documentation, unresolved inventory discrepancies, outdated procedures, and missing corrective action evidence can complicate audits.

Financial exposure: Unsupported transactions may lead to audit findings, repayment obligations, or further corrective action.

Preventive control: Maintain auditable transaction records, document exception resolution, and periodically test eligibility, Medicaid billing, inventory, and contract pharmacy controls.

HRSA audits examine covered entity eligibility, diversion, duplicate discounts, registration accuracy, and transaction records. 

Prioritizing 340B Billing Corrections by Risk

Not every 340B billing mistake requires the same response. Hospitals should first determine whether the finding affects program compliance, claim reimbursement, or purchasing accuracy.

A billing correction does not necessarily resolve a related compliance problem. Similarly, correcting an accumulation error does not automatically establish a claim underpayment.

AnnexMed observation: A useful 340B exception report should identify the affected transaction, its financial or compliance consequence, the responsible team, and the status of corrective action. Counting exceptions without distinguishing their causes provides limited guidance for hospital leadership.

Protecting Hospital Revenue Through Accurate 340B Billing 

340B billing accuracy depends on more than maintaining eligible drug purchases. Hospitals must ensure that patient eligibility, drug utilization, claim details, and reimbursement records remain consistent across pharmacy and revenue cycle operations. When these records are not reconciled, billing discrepancies can go undetected, creating financial exposure and compliance risks.

AnnexMed helps hospitals address these gaps through specialized 340B billing and revenue cycle support. Its capabilities include pharmacy charge validation, claims processing, payment reconciliation, and underpayment analysis, alongside 340B program services that support eligibility verification and transaction reconciliation. By connecting these activities, AnnexMed helps hospitals identify recurring billing errors, resolve reimbursement discrepancies, and strengthen the financial controls supporting their 340B programs.